AZN: Astrazeneca PLC insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
Up to 20 Phase 2 or 3 trials by Astrazeneca PLC with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-08-10 | Domvanalimab | Non-Small Cell Lung Cancer | Phase 3 | 791 | Enrollment complete | NCT05211895 |
| 2026-08-10 | Nexium 20mg | Erosive Esophagitis | Phase 3 | 53 | Completed | NCT05267613 |
| 2026-08-10 | AZD7798 | Crohn's Disease | Phase 2 | 24 | Enrollment complete | NCT06681324 |
| 2026-08-14 | AZD0901 | Gastric Cancer | Phase 2 | 33 | Enrollment complete | NCT07143604 |
| 2026-08-17 | Volrustomig | Metastatic Non-small Cell Lung Cancer | Phase 3 | 895 | Enrollment complete | NCT05984277 |
| 2026-08-24 (est.) | Danicopan | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | 80 | Enrollment complete | NCT05389449 |
| 2026-08-28 (est.) | AZD2936 | Non-Small-Cell Lung Carcinoma | Phase 1/2 | 212 | Enrollment complete | NCT04995523 |
| 2026-09-03 | AZD0780 | Dyslipidaemia | Phase 2 | 76 | Completed | NCT07218900 |
| 2026-09-21 | ICS-LABA | Eosinophilic Asthma | Phase 3 | 130 | Completed | NCT06750289 |
| 2026-09-26 (est.) | Zibotentan/Dapagliflozin | Chronic Kidney Disease With High Proteinuria | Phase 2 | 224 | Enrollment complete | NCT06942910 |
| 2026-09-30 (est.) | Durvalumab | Hepatocellular Carcinoma | Phase 3 | 214 | Enrollment complete | NCT05557838 |
| 2026-09-30 (est.) | Oleclumab | Non-Small Cell Lung Cancer | Phase 3 | 1,051 | Enrollment complete | NCT05221840 |
| 2026-10-01 | AZD6489 | RSV Respiratory Syncytial Virus | Phase 1/2 | 164 | Enrollment complete | NCT07717840 |
| 2026-10-23 (est.) | AZD6234 | Obesity/Overweight | Phase 2 | 16 | Enrollment complete | NCT07017179 |
| 2026-10-23 (est.) | Durvalumab | Carcinoma, Non-Small-Cell Lung | Phase 2 | 103 | Enrollment complete | NCT06008093 |
| 2026-10-27 (est.) | Volrustomig | Hepatocellular Carcinoma | Phase 2 | 294 | Enrollment complete | NCT05775159 |
| 2026-10-31 (est.) | Capivasertib | Breast Cancer | Phase 3 | 293 | Enrollment complete | NCT06635447 |
| 2026-11-02 (est.) | Anifrolumab | Cutaneous Lupus Erythematosus | Phase 3 | 339 | Enrollment complete | NCT06015737 |
| 2026-11-05 (est.) | AZD9750 | Prostate Cancer | Phase 1/2 | 6 | Enrollment complete | NCT07336446 |
| 2026-11-17 (est.) | AZD0901 | Gastric Cancer | Phase 2 | 226 | Recruiting | NCT06219941 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.